¶ KCNK18 Protein — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)
| KCNK18 Protein (TRESK) |
|---|
| Protein Name | Potassium Two Pore Domain Channel Subfamily K Member 18 |
| Gene | [KCNK18](/genes/kcnk18) |
| UniProt ID | [Q9HB98](https://www.uniprot.org/uniprot/Q9HB98) |
| PDB ID | 3UM7 |
| Molecular Weight | ~38 kDa (320 amino acids) |
| Subcellular Localization | Cell membrane (plasma membrane) |
| Protein Family | K2P (Two-pore domain potassium) channel family |
| Brain Expression | Trigeminal ganglion, dorsal root ganglion, hippocampus |
KCNK18, also known as TRESK (Two-pore domain potassium channel related to segmental polarity, also termed TWIK-related spinal cord potassium channel), is a member of the two-pore domain potassium (K2P) channel family. K2P channels are a diverse family of background potassium channels that regulate cellular excitability by providing resting membrane conductance and responding to various physiological stimuli. TRESK is unique among K2P channels due to its regulation by calcineurin, a calcium-activated phosphatase, which provides a direct link between intracellular calcium signaling and neuronal excitability.
TRESK is expressed primarily in sensory neurons, including trigeminal ganglion neurons and dorsal root ganglion (DRG) neurons, where it plays critical roles in regulating pain signaling and neuronal excitability. The channel has attracted significant attention in migraine research following the discovery that mutations in KCNK18 cause familial migraine with aura. Beyond migraine, TRESK has been implicated in chronic pain states, epilepsy, and other neurological disorders involving neuronal hyperexcitability.
This comprehensive page covers TRESK's molecular structure, its physiological functions in the nervous system, its role in neurological diseases, and its potential as a therapeutic target.
¶ Structure and Molecular Architecture
TRESK is a member of the K2P channel family, which is characterized by the presence of two pore-forming domains in each subunit. Unlike voltage-gated potassium channels that contain six transmembrane segments, K2P channels contain four transmembrane segments with two pore domains (P1 and P2). TRESK forms functional homodimers to create a channel with four pore domains (two from each subunit).
¶ Domain Organization
flowchart TD
A["TRESK Dimer<br/>2 x 320 aa"] --> B["N-terminal<br/>Domain"]
A --> C["Transmembrane<br/>Segments M1-M4"]
A --> D["Pore Domains<br/>P1 and P2"]
A --> E["C-terminal<br/>Calcineurin<br/>Binding Domain"]
B --> F["Calcineurin<br/>Activation Site"]
C --> G["Voltage<br/>Independence"]
D --> H["K+ Selectivity<br/>Filter"]
E --> I["Calcium-dependent<br/>Regulation"]
G --> J["Background<br/>Conductance"]
H --> K["Resting<br/>Membrane Potential"]
I --> L["Activity-dependent<br/>Modulation"]
N-terminal Domain:
- Contains the calcineurin binding site
- Mediates calcium-dependent activation
- Regulates channel trafficking to the membrane
Transmembrane Segments (M1-M4):
- Four transmembrane helices per subunit
- M1 and M4 contribute to the pore structure
- M2 and M3 form the selectivity filter
- The channel is voltage-independent
Pore Domains:
- P1 and P2 contain the K+ selectivity filter (GYG signature sequence)
- The selectivity filter determines potassium selectivity
- Pore loops between M2 and M3 form the narrow conduction pathway
C-terminal Domain:
- Contains the calcineurin docking motif
- Mediates calcium-dependent activation
- Contains regulatory phosphorylation sites
The crystal structure of TRESK (PDB: 3UM7) revealed several unique features:
Dimer Architecture:
- Two identical subunits form a functional dimer
- Each subunit contributes two pore domains
- The dimer creates a pseudo-symmetric channel with four pores
Calcineurin Activation:
- Calcineurin binds to a specific motif in the N-terminus
- Dephosphorylation activates the channel
- Provides a unique calcium-dependent activation mechanism
Selectivity Filter:
- Classical K+ selectivity sequence (GYG)
- Permits rapid K+ conduction
- Blocked by barium and other cations
TRESK activity is modulated by several post-translational mechanisms:
Calcineurin-dependent Dephosphorylation:
- Activation by calcium-activated calcineurin
- Rapid response to increases in intracellular calcium
- Unique among K2P channels
Phosphorylation:
- Basal phosphorylation maintains channel activity
- Protein kinase A can modulate function
- Multiple serine/threonine sites
Glycosylation:
- N-linked glycosylation in the extracellular loops
- Affects channel trafficking and surface expression
TRESK plays a critical role in regulating the excitability of sensory neurons:
Resting Membrane Potential:
- Provides background K+ conductance
- Maintains negative resting membrane potential
- Reduces neuronal excitability
Pain Signaling:
- TRESK activity counteracts pain transmission
- Channel activation reduces nociceptor firing
- Contributes to analgesia under normal conditions
Thermal Sensation:
- TRESK modulates responses to thermal stimuli
- Contributes to heat and cold detection
- Affects pain perception at extreme temperatures
TRESK is highly expressed in the trigeminal ganglion, making it particularly relevant to craniofacial pain:
Migraine Pathogenesis:
- TRESK regulates trigeminal neuron excitability
- Dysfunction may contribute to migraine attacks
- Trigeminal activation triggers migraine pain
Vascular Tone:
- TRESK may regulate cerebrovascular tone
- Affects meningeal blood flow
- Possible role in cortical spreading depression
TRESK contributes to overall neuronal excitability control:
Homeostatic Regulation:
- Adjusts resting membrane conductance
- Responds to metabolic stress
- Protects against hyperexcitability
Activity-Dependent Modulation:
- Calcineurin activation provides feedback
- Increased neuronal activity can activate TRESK
- Negative feedback on excitability
TRESK has emerged as a significant player in migraine pathophysiology:
Genetic Evidence:
- KCNK18 mutations cause autosomal dominant familial migraine with aura
- Mutations produce loss-of-function channels
- Reduced TRESK activity leads to increased neuronal excitability
Mechanism:
- TRESK loss-of-function increases trigeminal neuron excitability
- Enhanced neuronal firing promotes migraine attacks
- Cortical spreading depression may be facilitated
Phenotype:
- Migraine attacks with visual aura
- Photophobia and phonophobia
- Variable attack frequency and severity
Polymorphism Studies:
- Certain KCNK18 variants associated with sporadic migraine risk
- Common variants may modify channel function
- Gene-environment interactions in migraine susceptibility
Therapeutic Implications:
- TRESK modulators represent novel migraine treatment approach
- Targeting TRESK may provide prophylactic benefit
- Selective activation could reduce attack frequency
TRESK contributes to chronic pain states through several mechanisms:
Neuropathic Pain:
- TRESK dysfunction in DRG neurons contributes to neuropathic pain
- Downregulation of TRESK observed in chronic pain models
- Contributes to hyperexcitability of nociceptors
Inflammatory Pain:
- TRESK activity modulated in inflammatory conditions
- Changes in channel expression affect pain sensitivity
- Potential therapeutic target
Migraine-Associated Pain:
- Trigeminal TRESK dysfunction in chronic migraine
- Central sensitization mechanisms
- Refractory migraine connections
TRESK has been implicated in epilepsy through channelopathy mechanisms:
Channelopathy:
- TRESK mutations identified in patients with epilepsy
- Loss-of-function leads to neuronal hyperexcitability
- Contributes to seizure generation
Therapeutic Potential:
- TRESK activators may reduce seizure frequency
- Modulating neuronal excitability via TRESK
- Novel approach to epilepsy treatment
Anxiety and Depression:
- TRESK expressed in brain regions involved in mood
- Possible role in emotional regulation
- Requires further investigation
Neuroprotection:
- TRESK activity may protect against excitotoxicity
- Potential role in neurodegenerative diseases
- May modulate neuronal survival pathways
| Partner |
Interaction Type |
Functional Significance |
| Calcineurin |
Direct activation |
Calcium-dependent regulation |
| PKA |
Phosphorylation |
Modulates channel activity |
| PKC |
Phosphorylation |
Alters trafficking and function |
TRESK interacts with other potassium channel families:
- Coordinates neuronal excitability control
- Redundant mechanisms for membrane potential regulation
- Compensation between channel types
Calcineurin Pathway:
- Direct calcium-dependent activation
- Unique among K2P channels
- Provides activity-dependent feedback
Other Calcium Channels:
- TRESK responds to calcium influx through other channels
- Coordination between calcium entry and potassium efflux
- Activity-dependent regulation of excitability
KCNK18 Knockout Mice:
- Show increased pain sensitivity
- Enhanced neuronal excitability
- Migraine-related phenotypes
TRESK Overexpression:
- Reduced pain behavior
- Decreased neuronal excitability
- Protective against hyperexcitability
- Migraine models show TRESK involvement
- Chronic pain models demonstrate TRESK dysfunction
- Epilepsy models reveal channelopathy connections
TRESK represents a promising therapeutic target for several conditions:
TRESK Activators:
- Small molecules that enhance TRESK activity
- Potential for prophylactic treatment
- May reduce attack frequency and severity
Advantages:
- Peripheral target (trigeminal ganglion)
- Limited CNS side effects
- Novel mechanism of action
Analgesic Development:
- TRESK modulators for chronic pain
- Alternative to opioid-based analgesia
- Non-addictive pain relief
Approaches:
- Direct channel activators
- Compounds that enhance channel trafficking
- Gene therapy approaches
Specificity:
- Achieving selectivity for TRESK over other K2P channels
- Avoiding off-target effects
- Maintaining proper physiological function
Delivery:
- Targeting to trigeminal ganglion
- CNS penetration requirements
- Local vs. systemic delivery
Safety:
- Cardiovascular effects (K2P expression in heart)
- Sedation and CNS effects
- Narrow therapeutic window
Cryo-EM Studies:
- High-resolution structures of TRESK in various states
- Understanding activation mechanisms
- Structure-based drug design
Mutagenesis Studies:
- Mapping functional domains
- Identifying regulatory sites
- Characterizing disease mutations
Biomarker Development:
- TRESK genetic testing for migraine risk
- Protein expression as disease marker
- Therapeutic response prediction
Clinical Trials:
- TRESK modulators in early-phase trials
- Safety and efficacy evaluation
- Dose optimization studies